Curis (CRIS) Debt Ratio (2012 - 2025)

Curis' (CRIS) quarterly Debt Ratio came in at 0.25 in Q3 2025, little changed on a QoQ basis from 0.25 in Q2 2025.

Curis (CRIS) Debt Ratio (2012 - 2025) Analysis & Trends

Curis (CRIS) has 12 years of Debt Ratio data on file, last reported at 0.25 in Q3 2025.

Quarterly Debt Ratio changed N/A year-over-year to 0.25 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 0.25 (changed N/A YoY) and the FY2024 annual result came in at 0.18, up 66.4% from the prior year.
Debt Ratio held at 0.25 in Q3 2025, from 0.25 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.25 in Q2 2025 to a low of 0.0 in Q1 2021.
A 4-year average of 0.16 and a median of 0.18 in 2024 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 66.4% in 2024, down 66.4% in 2024.
Tracing CRIS's Debt Ratio over 4 years: stood at 0.0 in 2021, then soared by 2253.82% to 0.11 in 2023, then surged by 66.4% to 0.18 in 2024, then surged by 37.34% to 0.25 in 2025.
The last three Debt Ratio figures came in at 0.25 (Q3 2025), 0.25 (Q2 2025), and 0.18 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Curis	3.44 Mn	-2.18 Mn	-	-

Download Data